{"title":"Clinical features, treatment and outcomes of dabrafenib-associated uveitis.","authors":"Jieqiong Liu, Wei Sun, Chunjiang Wang","doi":"10.1007/s10637-025-01569-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment.</p><p><strong>Methods: </strong>The database was retrieved to collect reports of dabrafenib-associated uveitis and clinical data were collected for retrospective analysis.</p><p><strong>Results: </strong>Twenty-six patients were included in the study, with a median age of 56 years (range 30, 75). The onset time of uveitis was 3 months (range 0.75, 96) after administration. The types of uveitis were pan-uveitis (38.5%), anterior uveitis (34.6%), posterior uveitis (15.4%), and intermediate uveitis (3.8%). Fifty percent of the patients were Vogt-Koyanagi-Harada disease-like uveitis. After discontinuation of dabrafenib and treatment with topical and systemic steroids, the symptoms of uveitis improved in all patients.</p><p><strong>Conclusion: </strong>Patients are advised to have regular ophthalmology examinations during the use of dabrafenib. Timely administration of systemic or local corticosteroid treatment can significantly improve the symptoms of patients.</p>","PeriodicalId":14513,"journal":{"name":"Investigational New Drugs","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Investigational New Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10637-025-01569-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment.
Methods: The database was retrieved to collect reports of dabrafenib-associated uveitis and clinical data were collected for retrospective analysis.
Results: Twenty-six patients were included in the study, with a median age of 56 years (range 30, 75). The onset time of uveitis was 3 months (range 0.75, 96) after administration. The types of uveitis were pan-uveitis (38.5%), anterior uveitis (34.6%), posterior uveitis (15.4%), and intermediate uveitis (3.8%). Fifty percent of the patients were Vogt-Koyanagi-Harada disease-like uveitis. After discontinuation of dabrafenib and treatment with topical and systemic steroids, the symptoms of uveitis improved in all patients.
Conclusion: Patients are advised to have regular ophthalmology examinations during the use of dabrafenib. Timely administration of systemic or local corticosteroid treatment can significantly improve the symptoms of patients.
期刊介绍：
The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
